You are viewing: Brazil Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The Brazil Cancer Biomarkers Market was valued at $678.8 Million in 2026 and projected to reach to $1268.1 Million by 2031, representing a compound annual growth rate of 11.0%. Brazil's cancer biomarkers market is positioned for significant growth through 2031, driven by rising cancer incidence rates and increasing healthcare expenditure on precision diagnostics.

Brazil Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Brazil Cancer Biomarkers Market Trends and Insights

  • This growth trajectory reflects Brazil's increasing investment in precision oncology and diagnostic infrastructure across both public and private healthcare systems.
  • Brazil's rising cancer incidence, coupled with growing adoption of personalized medicine approaches, is driving demand for advanced biomarker testing and companion diagnostics. The Brazilian market benefits from expanding healthcare access, improved reimbursement policies, and strengthening partnerships between local laboratories and international diagnostic companies.
  • Brazil's regulatory environment continues to evolve favorably for biomarker-based testing, supporting clinical adoption across major urban centers and emerging regional markets.
  • By 2031, Brazil is expected to consolidate its position as a leading Latin American hub for cancer biomarker innovation and clinical implementation..

Key Market Statistics

  • CAGR (2026-2031) 11.0% CAGR
  • Market Size, 2026 ~USD 678.8 Million
  • Forecast, 2031 ~USD 1268.1 Million
  • Country Brazil

Brazil Cancer Biomarkers Market Overview

Market Valuation Growth :

Brazil's cancer biomarkers market is valued at USD 678.8 million in 2026 and is projected to expand to USD 1,268.1 million by 2031, representing a robust 11% CAGR over the forecast period.

Precision Oncology Adoption :

Brazil is witnessing accelerated adoption of personalized medicine and precision oncology across both public healthcare systems (SUS) and private institutions, driving demand for advanced diagnostic biomarkers.

Rising Cancer Incidence :

Increasing cancer prevalence in Brazil, combined with improved healthcare access and awareness, is creating sustained demand for early detection and prognostic biomarker solutions.

Healthcare Infrastructure Investment :

Brazil's growing investment in diagnostic infrastructure and laboratory capabilities is enabling broader implementation of biomarker testing in oncology centers and regional hospitals.

Brazil Cancer Biomarkers Market Dynamics

  • The integration of biomarker testing into Brazil's public healthcare system (SUS) and expanding private sector adoption are key growth catalysts.
  • Healthcare providers are increasingly recognizing the clinical and economic value of biomarker-guided treatment decisions, particularly for lung, breast, and colorectal cancers. The market will benefit from technological advancements in molecular diagnostics, growing partnerships between Brazilian institutions and international biotech companies, and regulatory improvements facilitating faster adoption of novel biomarkers.
  • However, challenges including healthcare budget constraints and unequal access across regions may moderate growth in certain segments.
  • Overall, Brazil represents a high-potential market for biomarker developers and diagnostic service providers targeting Latin America..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • Brazil's cancer biomarkers market will nearly double from USD 678.8M (2026) to USD 1,268.1M (2031), representing an 11.0% CAGR.
      • Brazil's expanding public healthcare system and private diagnostic sector are driving widespread adoption of precision oncology biomarkers.
      • Brazil's regulatory improvements and reimbursement policies are accelerating clinical implementation of companion diagnostics and liquid biopsy testing.
      • Brazil's position as Latin America's largest economy positions it as a critical growth market for international and regional biomarker diagnostic providers.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      Brazil Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2024–2032

      Segment20242025202620272029203020312032CAGR (%)
      BIOPHARMACEUTICAL COMPANIES & CROS189204.9225.1248.2305.3341.4384.2432.811.5
      DIAGNOSTIC LABORATORIES457.3489.1530.4577.2691.1762.6846.6940.510
      OTHER END USERS33.935.337.239.444.547.751.455.36.8
      RESEARCH AND ACADEMIC INSTITUTES111.9120.7132144.8176.3196.2219.8246.311
      TOTAL792.1850924.71009.51217.21347.91501.91674.910.4

      Target Audience

      • In Vitro Diagnostics (IVD) Manufacturers : Biomarker test developers and diagnostic companies need Brazil-specific market sizing and growth forecasts to prioritize product launches, allocate R&D resources, and establish distribution partnerships in this high-growth market.
      • Pharmaceutical & Oncology Companies : Pharma firms developing targeted cancer therapies require detailed biomarker market data for Brazil to support companion diagnostic strategies, clinical trial planning, and market access negotiations with Brazilian healthcare authorities.
      • Healthcare Investors & Private Equity : Investment firms evaluating opportunities in Brazilian healthcare diagnostics need quantified market data, growth trajectories, and competitive dynamics to assess portfolio companies and identify acquisition targets.
      • Hospital Networks & Laboratory Operators : Brazilian healthcare institutions and diagnostic laboratories need market intelligence to justify biomarker testing infrastructure investments, negotiate supplier contracts, and plan service expansion across regions.
      • Healthcare Consultants & Strategy Firms : Consulting professionals advising clients on Brazil market entry, competitive positioning, or portfolio strategy require validated market data and forecasts to support client recommendations and strategic planning.

      Key Companies in the Brazil Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      Reasons to Buy this Report

      • Market Size & Growth Validation : Quantified market valuation for Brazil (USD 678.8M in 2026) with clear 5-year forecast trajectory enables accurate business planning, investment decisions, and revenue projections specific to the Brazilian market.
      • Competitive Landscape Intelligence : Understand Brazil-specific market dynamics, key players, and competitive positioning within the country's unique healthcare ecosystem combining public (SUS) and private sector opportunities.
      • Regulatory & Healthcare System Insights : Gain actionable intelligence on Brazil's healthcare regulations, reimbursement pathways, and institutional adoption patterns critical for market entry and commercialization strategies.
      • Precision Oncology Opportunity Assessment : Identify high-potential cancer types and biomarker segments in Brazil where precision medicine adoption is accelerating, enabling targeted product development and go-to-market strategies.
      • Regional Expansion Planning : Leverage Brazil market data as a foundation for broader Latin American expansion, with insights applicable to neighboring markets with similar healthcare infrastructure and cancer epidemiology.

      Frequently asked questions

      What is the projected market size for cancer biomarkers in Brazil by 2031?

      Brazil's cancer biomarkers market is projected to reach USD 1,268.1 million by 2031, growing from USD 678.8 million in 2026 at an 11.0% CAGR.

      What factors are driving growth in Brazil's cancer biomarkers market?

      Brazil's market growth is driven by rising cancer incidence, increased adoption of precision medicine, expanding healthcare infrastructure, improved reimbursement policies, and strengthening diagnostic partnerships.

      How does Brazil's cancer biomarkers market compare to other Latin American countries?

      Brazil, as Latin America's largest economy, represents the region's most significant cancer biomarkers market with the highest absolute market value and fastest adoption of advanced diagnostic technologies.

      What types of biomarkers are most in demand in Brazil?

      Brazil shows strong demand for companion diagnostics, liquid biopsy tests, genomic profiling, and immunotherapy biomarkers across major cancer types including lung, breast, and colorectal cancers.

      What regulatory changes are impacting Brazil's cancer biomarkers market?

      Brazil's regulatory environment is evolving to support faster approval of biomarker tests, improved reimbursement coverage through ANVISA and health authority guidelines, and increased clinical adoption standards.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status